Stockreport

Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology [Yahoo! Finance]

Aptevo Therapeutics Inc.  (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
PDF The study reported Objective Response Rate (ORR) of 40.4% in 57 evaluable patients, primary endpoint was met. The novel combination of mitazalimab and mFOLFIRINOX and [Read more]